Vivus reports weak sales of diet pill Qsymia

Wed May 8, 2013 7:50am EDT

May 8 (Reuters) - Vivus Inc reported weaker-than-expected quarterly sales of its diet drug Qsymia amid difficulties over reimbursement for obesity treatments and a restricted sales channel.

Net product revenue, reflecting sales of Qsymia, rose to $4.1 million in the first quarter from $2 million in the preceding quarter. The drug was launched late last year.

The company's net loss widened to $53.6 million, or 53 cents per share, from $18.8 million, or 20 cents per share, a year earlier.

Analysts had expected a loss of 51 cents per share on revenue of $5.2 million, according to Thomson Reuters I/B/E/S.

Qsymia was the first weight-loss pill to be launched in the United States in 13 years.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
Paulson545 wrote:
Legendary billionaire investor Dr Phillip Frost has been buying shares of OPK and SFES……………Seeking Alpha thinks OPK might make a bid for SFES…………………

May 08, 2013 8:08am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.